When to use biological agents in inflammatory bowel disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 7, 2012, Pages 1141-1149

  Corte, Crispin ^a   Saxena, Payal ^a   Tattersall, Stephen ^a   Selinger, Christian ^a   Leong, Rupert W ^a  

^a SYDNEY LOCAL HEALTH DISTRICT   (Australia)

Author keywords

Biological agent; Cell adhesion; Crohn's; Cytokine; Efficacy; Inflammation; Inflammatory bowel disease; Safety; Treatment; Tumor necrosis factor; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BRIAKINUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; DRUG ANTIBODY; GAMMA INTERFERON; GOLIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; LIVE VACCINE; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; NARCOTIC ANALGESIC AGENT; NATALIZUMAB; NEUTRALIZING ANTIBODY; PARACETAMOL; PLACEBO; RHUMAB B7; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; USTEKINUMAB; VEDOLIZUMAB;

ARTICLE; AUTOIMMUNE DISEASE; BREAST FEEDING; CANCER RISK; CLINICAL TRIAL (TOPIC); COLON RESECTION; CROHN DISEASE; DEMYELINATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECZEMA; ENTERITIS; HEART FAILURE; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; INFECTION RISK; INFUSION RELATED REACTION; INJECTION SITE REACTION; INTESTINE FISTULA; INTESTINE MUCOSA; LIVER FAILURE; LYMPHOMA; OPPORTUNISTIC INFECTION; POSTOPERATIVE PERIOD; PREGNANCY; PREMEDICATION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIATIC ECZEMA; RECURRENT DISEASE; REMISSION; RISK BENEFIT ANALYSIS; SCREENING; SIDE EFFECT; T CELL LYMPHOMA; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; WOUND HEALING;

EID: 84862680276     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07056.x     Document Type: Article

References (110)

1. Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004; 53: 1366-73.
2. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 2009; 361: 888-98.
3. Ahern PP, Izcue A, Maloy KJ, Powrie F. The interleukin-23 axis in intestinal inflammation. Immunol. Rev. 2008; 226: 147-59.
4. Rutgeerts P, Sandborn WJ, Feagan BG etal. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005; 353: 2462-76.
5. Sandborn WJ, Colombel JF, Enns R etal. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 2005; 353: 1912-25.
6. Medicare Australia. Crohn disease. Pharmaceutical Benefits Scheme (PBS), Medicare Australia Website: Available form URL:. cited 7 Jan 2012.
7. Hanauer SB, Feagan BG, Lichtenstein GR etal. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
8. Colombel JF, Sandborn WJ, Rutgeerts P etal. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
9. Sandborn WJ, Feagan BG, Stoinov S etal. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 2007; 357: 228-38.
10. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 2008; (1): CD006893.
11. Järnerot G, Hertervig E, Friis-Liby I etal. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.
12. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am. J. Gastroenterol. 2005; 100: 2031-5.
13. Abreu MT, Geller JL, Vasiliauskas EA etal. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J. Clin. Gastroenterol. 2006; 40: 55-63.
14. Miheller P, Muzes G, Rácz K etal. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. Inflamm. Bowel Dis. 2007; 13: 1379-84.
15. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821-2.
16. Herfarth H, Obermeier F, Andus T etal. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am. J. Gastroenterol. 2002; 97: 2688-90.
17. van der Heijde D, Kivitz A, Schiff MH etal. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006; 54: 2136-46.
18. Targan SR, Hanauer SB, van Deventer SJ etal. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 1997; 337: 1029-35.
19. Rutgeerts P, D'Haens G, Targan S etal. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
20. Rutgeerts P, Feagan BG, Lichtenstein GR etal. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13.
21. Schnitzler F, Fidder H, Ferrante M etal. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
22. Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J. Gastroenterol. Hepatol. 2009; 24: 1252-7.
23. Hanauer SB, Sandborn WJ, Rutgeerts P etal. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
24. Schreiber S, Khaliq-Kareemi M, Lawrance IC etal. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 2007; 357: 239-50.
25. Sandborn WJ, Hanauer SB, Rutgeerts P etal. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9.
26. Lichtenstein GR, Thomsen OØ, Schreiber S etal. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18months. Clin. Gastroenterol. Hepatol. 2010; 8: 600-9.
27. Sands BE, Anderson FH, Bernstein CN etal. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 2004; 350: 876-85.
28. Kamm MA. Review article: biologic drugs in Crohn's disease. Aliment. Pharmacol. Ther. 2006; 24 (Suppl. 3): 80-9.
29. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-9.
30. Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin. Gastroenterol. Hepatol. 2004; 2: 912-20.
31. Uchino M, Ikeuchi H, Bando T etal. Long-term efficacy of infliximab maintenance therapy for perianal Crohn's disease. World J. Gastroenterol. 2011; 17: 1174-9.
32. Regueiro M, Schraut W, Baidoo L etal. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136: 441-50e1.
33. Yoshida K, Fukunaga K, Ikeuchi H etal. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm. Bowel Dis. 2012, doi: 10.1002/ibd.21928.
34. De Cruz PP, Bernardi M-P, Allen PB etal. Post-operative Crohn's disease recurrence: impact of endoscopic monitoring and treatment step-up on outcome. Gastroenterology 2011; 140 (Suppl 1): 782.
35. Panaccione R, Ghosh S, Middleton S etal. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial. J. Crohns Colitis 2011; 5: S8.
36. Russo EA, Harris AW, Campbell S etal. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment. Pharmacol. Ther. 2009; 29: 308-14.
37. Su C, Salzberg BA, Lewis JD etal. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am. J. Gastroenterol. 2002; 97: 2577-84.
38. Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A etal. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008; 55: 1609-14.
39. Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment. Pharmacol. Ther. 2010; 32: 522-8.
40. Sandborn WJ, Van Assche G, Reinisch W etal. Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2011; 140: S123-S4.
41. Dean KE, Hikaka J, Huakau JT, Walmsley RS. Infliximab or cyclosporine for acute severe ulcerative colitis: A retrospective analysis. J. Gastroenterol. Hepatol. 2012 (in press).
42. Laharie D, Boureille A, Branche J etal. Ciclosporin versus infliximab in acute severe ulcerative colitis refractory to intravenous steroids: a randomized study. J. Crohns Colitis 2011; 5: S8.
43. Schreiber S, Reinisch W, Colombel JF etal. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology 2007; 132 (Suppl. 2): A147. Abstract 985.
44. Cosnes J, Cattan S, Blain A etal. Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis. 2002; 8: 244-50.
45. D'Haens G, Baert F, van Assche G etal. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7.
46. Baert F, Moortgat L, Van Assche G etal. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010 138: 463-8.
47. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-6.
48. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand. J. Gastroenterol. 2008; 43: 948-54.
49. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am. J. Gastroenterol. 2009; 104: 760-7.
50. Karmiris K, Paintaud G, Noman M etal. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
51. Radstake TR, Svenson M, Eijsbouts AM etal. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 2009; 68: 1739-45.
52. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment. Pharmacol. Ther. 2008; 28: 1122-6.
53. Hanauer SB, Wagner CL, Bala M etal. Incidence and importance of antibody responses to infl iximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2004; 2: 542-53.
54. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
55. Schnitzler F, Fidder H, Ferrante M etal. Flexibility in interval and dosing of infliximab enables maintained response of patients with Crohn's disease. Gastroenterology 2008; 134 (Suppl. 1): A658.
56. Sandborn WJ, Rutgeerts P, Enns R etal. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 2007; 146: 829-38.
57. Allez M, Vermeire S, Mozziconacci N etal. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment. Pharmacol. Ther. 2010; 31: 92-101.
58. Connell W, Andrews JM, Brown S, Sparrow M. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. Intern. Med. J. 2010; 40: 139-49.
59. Sandborn WJ, Hanauer S, Loftus EV etal. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am. J. Gastroenterol. 2004; 99: 1984-9.
60. Youdim A, Vasiliauskas EA, Targan SR etal. A pilot study of adalimumab in infliximab-allergic patients. Inflamm. Bowel Dis. 2004; 10: 333-8.
61. Papadakis KA, Shaye OA, Vasiliauskas EA etal. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am. J. Gastroenterol. 2005; 100: 75-9.
62. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment. Pharmacol. Ther. 2007; 25: 675-80.
63. Hinojosa J, Gomollón F, García S etal. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment. Pharmacol. Ther. 2007; 25: 409-18.
64. Sandborn WJ, Vermeire S, Abreu MT, D'Haens G etal. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin. Gastroenterol Hepatol. 2010; 8: 688-95.
65. Van Assche GA, Vermeire S, Ballet V etal. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012; 61: 229-34.
66. Lichtenstein GR, Feagan BG, Cohen RD etal. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 2006; 4: 621-30.
67. Fidder H, Schnitzler F, Ferrante M etal. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8.
68. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun. Rev. 2008; 8: 147-52.
69. Toruner M, Loftus EV Jr, Harmsen WS etal. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36.
70. Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum. 2008; 58: 947-52.
71. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V etal. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005; 52: 1766-72.
72. Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF- alpha treatments. Rheumatology (Oxford) 2005; 44: 1205-6.
73. Ooi CJ, Fock KM, Makharia GK etal. The Asia-Pacific consensus on ulcerative colitis. J. Gastroenterol. Hepatol. 2010; 25: 453-68.
74. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin. Gastroenterol. Hepatol. 2004; 2: 309-13.
75. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008; 57: 549-58.
76. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-5.
77. Beaugerie L, Brousse N, Bouvier AM etal. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
78. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 2009; 7: 874-81.
79. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008; 57: 1639-41.
80. Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J. Crohns Colitis 2010; 4: 511-22. Epub 2010 Jun 25.
81. Biancone L, Orlando A, Kohn A etal. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006; 55: 228-33.
82. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
83. Vermeire S, Noman M, Van Assche G etal. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125: 32-9.
84. Lipsky PE, van der Heijde DM, St Clair EW etal. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 2000; 343: 1594-602.
85. Ramos-Casals M, Brito-Zerón P, Muñoz S etal. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86: 242-51.
86. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt. Sinai. J. Med. 2005; 72: 250-6.
87. van Oosten BW, Barkhof F, Truyen L etal. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-4.
88. Mohan N, Edwards ET, Cupps TR etal. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001; 44: 2862-9.
89. Schiff MH, Burmester GR, Kent JD etal. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis. 2006; 65: 889-94.
90. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-40.
91. Colombel JF, Sandborn WJ, Reinisch W etal. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 2010; 362: 1383-95.
92. Feagan B, McDonald JW, Panaccione R etal. A randomized trial of methotrexate in combination with Infliximab for the treatment of Crohn's disease. Gastroenterology 2008; 135: 294-5.
93. Hutfless S, Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2008; 28: 598-605.
94. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm. Bowel Dis. 2009; 15: 1410-16.
95. Rahier JF, Yazdanpanah Y, Colombel JF, Travis S. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? Gut 2009; 58: 1313-15.
96. Rahier JF, Ben-Horin S, Chowers Y etal. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
97. Bhatia J, Bratcher J, Korelitz B etal. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J. Gastroenterol. 2006; 12: 6167-71.
98. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am. J. Gastroenterol. 2008; 103: 631-6.
99. D'Haens G. Anti-TNF treatment in Crohn's disease: toward tailored therapy? Am. J. Gastroenterol. 2010; 105: 1140-1.
100. Van Assche G, Magdelaine-Beuzelin C, D'Haens G etal. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8.
101. Drobne D, Bossuyt PM, Breynaert C etal. Long term evolution and impact of immunomodulator co-treatment and withdrawal on infliximab trough levels in 223 patients with Crohn's disease. J. Crohns Colitis 2011; 5: S10-11.
102. Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am. J. Gastroenterol. 2010; 105: 1142-9.
103. Louis E, Vernier-Massouille G, Grimaud J etal. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut 2008; 57: A66.
104. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J. Rheumatol. 2009; 36: 635-41.
105. O'Donnell S, O'Morain C. Review article: use of anti tumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment. Pharmacol. Ther. 2008; 27: 885-94.
106. Mahadevan U, Kane S, Sandborn WJ etal. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment. Pharmacol. Ther. 2005; 21: 733-8.
107. Vasiliauskas EA, Church JA, Silverman N etal. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin. Gastroenterol. Hepatol. 2006; 4: 1255-8.
108. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 2005; 54: 890-900.
109. Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab for Crohn's disease in pregnancy. Inflamm. Bowel Dis. 2006; 12: 827-8.
110. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011; 17: 958-63.